JPRN-jRCTs031180255招募中3 期
JCOG1507: A phase III trial to confirm S-1 adjuvant chemotherapy for pathological stage II/III vulnerable elderly gastric cancer patients who underwent gastric resection - BIRDIE
YOSHIDA Kazuhiro0 个研究点目标入组 170 人开始时间: 2019年3月13日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 80age old 至 ot applicable(—)
- 性别
- All
入选标准
- •1) Histologically proven gastric adenocarcinoma
- •2) Pathological stage II/III defined by 14th edition of Japanese Classification of Gastric Carcinoma
- •3) Received R0 gastrectomy with D1+ or D2 lymphadenectomy
- •4) Either of the following surgery performed;
- •i) Open laparotomy regardless of clinical stage and type of gastrectomy
- •ii) Laparoscopic or laparoscope-assisted gastrectomy regardless of clinical stage and type of gastrectomy
- •5) Either of the followings:
- •i) Weight loss < 15% and 30 mL/min <= Ccr for the patients received total gastrectomy
- •ii) Weight loss < 15% and 30 mL/min <= Ccr < 80 mL/min for the patients not received total gastrectomy
- •6) Within 5 to 12 weeks after surgery
- •7) Aged 80 years old or older
- •8) Performance status of 0 or 1
- •9) No gastric stump cancer
- •10) No previous treatment of chemotherapy, radiation therapy, or molecular-target therapy for any neoplasms. (History of hormone therapy more than one year ago is eligible.)
- •11) Enough oral intake
- •12) No dementia, or dementia with family support to continue protocol treatment or examinations
- •13) Sufficient organ functions
- •14) No ischemic change on ECG
- •15) Written informed consent
排除标准
- •1) Synchronous double/multiple cancer or metachronous double/multiple cancer with progression free period of 5 years or shorter
- •2) Infectious disease requiring systemic treatment
- •3) Body temperature of 38 degrees Celsius or higher
- •4) Severe mental disease
- •5) Requiring systemic steroid medication (>= 5 mg/day of prednisolone)
- •6) Under treatment by flucytosine, phenytoin, or warfarin potassium
- •7) Uncontrolled diabetes mellitus
- •8) Uncontrolled hypertension
- •9) Unstable angina pectoris (angina developed or attack worsened within recent 3 weeks) or previous myocardial infarction within 6 months
- •10) Positive for HBs antigen
- •11) Severe interstitial pneumonia, severe lung fibrosis, or severe emphysema
- •12) Surgical morbidity such as infection, leakage, intestinal bleeding, pancreatic fistula, and so on is not improved
研究者
相似试验
招募中
3 期
A phase III trial to confirm S-1 adjuvant chemotherapy for pathological stage II/III vulnerable elderly gastric cancer patients who underwent gastric resection (JCOG1507, BIRDIE)Gastric neoplasmJPRN-UMIN000025742Japan Clinical Oncology Group (JCOG)370
已完成
3 期
Randomized phase III trial comparing adjuvant S-1 to capecitabine in stage III colorectal cancer (JCOG0910, CRC Adj-CAPS)Stage III colorectal cancerJPRN-UMIN000003272Japan Clinical Oncology Group(JCOG)1,550
进行中(未招募)
3 期
JCOG1403: Phase III trial of a single early intravesical instillation of pirarubicin in the prevention of bladder recurrence after nephroureterectomy for upper tract urothelial carcinomaJPRN-jRCTs031180121ITO Akihiro310
招募中
3 期
JCOG1509: Phase III trial to evaluate the efficacy of neoadjuvant chemotherapy with S-1 plus oxaliplatin followed by D2 gastrectomy with adjuvant S-1 in locally advanced gastric cancer.Gastric cancerJPRN-jRCTs031180350TERASHIMA Masanori470
进行中(未招募)
2 期
JCOG1306:Randomized phase II/III study of adjuvant chemotherapy with Adriamycin+Ifosfamide vs Gemcitabine+Docetaxel for high-grade soft tissue sarcoma ( AI vs GD for STS RPII/III )JPRN-jRCTs031180003Ozaki Toshifumi140
